vs

Side-by-side financial comparison of AMREP CORP. (AXR) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.

AMREP CORP. is the larger business by last-quarter revenue ($14.6M vs $9.2M, roughly 1.6× Foghorn Therapeutics Inc.). AMREP CORP. runs the higher net margin — 21.6% vs -234.3%, a 255.9% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 93.8%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -13.6%).

AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.

AXR vs FHTX — Head-to-Head

Bigger by revenue
AXR
AXR
1.6× larger
AXR
$14.6M
$9.2M
FHTX
Growing faster (revenue YoY)
FHTX
FHTX
+130.0% gap
FHTX
223.8%
93.8%
AXR
Higher net margin
AXR
AXR
255.9% more per $
AXR
21.6%
-234.3%
FHTX
Faster 2-yr revenue CAGR
FHTX
FHTX
Annualised
FHTX
35.3%
-13.6%
AXR

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
AXR
AXR
FHTX
FHTX
Revenue
$14.6M
$9.2M
Net Profit
$3.1M
$-21.7M
Gross Margin
Operating Margin
20.6%
-258.2%
Net Margin
21.6%
-234.3%
Revenue YoY
93.8%
223.8%
Net Profit YoY
338.9%
-11.1%
EPS (diluted)
$0.58
$-0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXR
AXR
FHTX
FHTX
Q1 26
$14.6M
Q4 25
$9.4M
$9.2M
Q3 25
$17.9M
$8.2M
Q2 25
$11.2M
$7.6M
Q1 25
$7.5M
$6.0M
Q4 24
$11.9M
$2.9M
Q3 24
$19.1M
$7.8M
Q2 24
$19.5M
$6.9M
Net Profit
AXR
AXR
FHTX
FHTX
Q1 26
$3.1M
Q4 25
$1.2M
$-21.7M
Q3 25
$4.7M
$-15.8M
Q2 25
$3.9M
$-17.9M
Q1 25
$717.0K
$-18.8M
Q4 24
$4.0M
$-19.5M
Q3 24
$4.1M
$-19.1M
Q2 24
$4.1M
$-23.0M
Operating Margin
AXR
AXR
FHTX
FHTX
Q1 26
20.6%
Q4 25
11.9%
-258.2%
Q3 25
34.4%
-226.9%
Q2 25
31.7%
-279.2%
Q1 25
5.7%
-385.0%
Q4 24
26.4%
-840.5%
Q3 24
26.1%
-305.5%
Q2 24
23.9%
-386.6%
Net Margin
AXR
AXR
FHTX
FHTX
Q1 26
21.6%
Q4 25
12.8%
-234.3%
Q3 25
26.3%
-194.4%
Q2 25
34.8%
-237.3%
Q1 25
9.5%
-316.4%
Q4 24
33.9%
-682.9%
Q3 24
21.3%
-244.9%
Q2 24
21.2%
-333.6%
EPS (diluted)
AXR
AXR
FHTX
FHTX
Q1 26
$0.58
Q4 25
$0.22
$-0.35
Q3 25
$0.87
$-0.25
Q2 25
$0.73
$-0.28
Q1 25
$0.13
$-0.30
Q4 24
$0.75
$-0.23
Q3 24
$0.76
$-0.31
Q2 24
$0.77
$-0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXR
AXR
FHTX
FHTX
Cash + ST InvestmentsLiquidity on hand
$50.0M
$80.9M
Total DebtLower is stronger
$21.0K
Stockholders' EquityBook value
$139.4M
$-108.5M
Total Assets
$143.9M
$198.1M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXR
AXR
FHTX
FHTX
Q1 26
$50.0M
Q4 25
$44.6M
$80.9M
Q3 25
$48.9M
$89.3M
Q2 25
$39.5M
$72.6M
Q1 25
$36.9M
$61.0M
Q4 24
$40.1M
$55.5M
Q3 24
$40.4M
$57.7M
Q2 24
$29.7M
$138.9M
Total Debt
AXR
AXR
FHTX
FHTX
Q1 26
$21.0K
Q4 25
$23.0K
Q3 25
$25.0K
Q2 25
$26.0K
Q1 25
$29.0K
Q4 24
$32.0K
Q3 24
$34.0K
Q2 24
$35.0K
Stockholders' Equity
AXR
AXR
FHTX
FHTX
Q1 26
$139.4M
Q4 25
$136.0M
$-108.5M
Q3 25
$134.7M
$-89.7M
Q2 25
$130.0M
$-76.7M
Q1 25
$126.0M
$-61.7M
Q4 24
$125.1M
$-45.5M
Q3 24
$122.2M
$-28.3M
Q2 24
$118.0M
$-14.3M
Total Assets
AXR
AXR
FHTX
FHTX
Q1 26
$143.9M
Q4 25
$140.1M
$198.1M
Q3 25
$140.7M
$205.0M
Q2 25
$133.8M
$226.2M
Q1 25
$128.9M
$258.7M
Q4 24
$129.1M
$284.0M
Q3 24
$127.0M
$308.4M
Q2 24
$122.8M
$328.6M
Debt / Equity
AXR
AXR
FHTX
FHTX
Q1 26
0.00×
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXR
AXR
FHTX
FHTX
Operating Cash FlowLast quarter
$5.4M
$-22.3M
Free Cash FlowOCF − Capex
$5.4M
FCF MarginFCF / Revenue
37.0%
Capex IntensityCapex / Revenue
0.1%
0.0%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$20.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXR
AXR
FHTX
FHTX
Q1 26
$5.4M
Q4 25
$-4.3M
$-22.3M
Q3 25
$9.5M
$-18.9M
Q2 25
$10.2M
$-21.0M
Q1 25
$-3.2M
$-24.0M
Q4 24
$-182.0K
$-24.5M
Q3 24
$10.7M
$-21.0M
Q2 24
$10.7M
$-25.5M
Free Cash Flow
AXR
AXR
FHTX
FHTX
Q1 26
$5.4M
Q4 25
$-4.3M
Q3 25
$9.5M
Q2 25
$9.7M
$-21.0M
Q1 25
$-3.3M
$-24.0M
Q4 24
$-268.0K
$-25.0M
Q3 24
$10.7M
$-21.3M
Q2 24
$10.3M
$-25.6M
FCF Margin
AXR
AXR
FHTX
FHTX
Q1 26
37.0%
Q4 25
-45.9%
Q3 25
53.2%
Q2 25
86.4%
-278.2%
Q1 25
-43.4%
-403.2%
Q4 24
-2.3%
-875.3%
Q3 24
55.8%
-273.0%
Q2 24
52.5%
-371.0%
Capex Intensity
AXR
AXR
FHTX
FHTX
Q1 26
0.1%
Q4 25
0.6%
0.0%
Q3 25
0.1%
0.0%
Q2 25
5.2%
0.3%
Q1 25
0.3%
0.5%
Q4 24
0.7%
16.8%
Q3 24
0.2%
4.0%
Q2 24
2.3%
0.2%
Cash Conversion
AXR
AXR
FHTX
FHTX
Q1 26
1.72×
Q4 25
-3.54×
Q3 25
2.03×
Q2 25
2.63×
Q1 25
-4.51×
Q4 24
-0.05×
Q3 24
2.63×
Q2 24
2.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons